{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:33:46Z","timestamp":1787625226125,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01302-z","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:01:17Z","timestamp":1756375277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Primary Intrahepatic Biliary Neuroendocrine Neoplasms: A Case Report and Literature Review"],"prefix":"10.1007","volume":"56","author":[{"given":"Zhengfu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyong","family":"E","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"1","key":"1302_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0218-3","volume":"36","author":"C Fang","year":"2017","unstructured":"Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Chin J Cancer. 2017;36(1): 51. https:\/\/doi.org\/10.1186\/s40880-017-0218-3.","journal-title":"Chin J Cancer"},{"issue":"10","key":"1302_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1302_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2","volume":"79","author":"IM Modlin","year":"1997","unstructured":"Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79(4):813\u201329. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970215)79:4%3c813::aid-cncr19%3e3.0.co;2-2.","journal-title":"Cancer"},{"issue":"4","key":"1302_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12253-014-9808-4","volume":"20","author":"N Michalopoulos","year":"2014","unstructured":"Michalopoulos N, Papavramidis TS, Karayannopoulou G, Pliakos I, Papavramidis ST, Kanellos I. Neuroendocrine tumors of extrahepatic biliary tract. Pathol Oncol Res. 2014;20(4):765\u201375. https:\/\/doi.org\/10.1007\/s12253-014-9808-4.","journal-title":"Pathol Oncol Res"},{"issue":"10","key":"1302_CR5","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<1959::AID-CNCR12>3.0.CO;2-H","volume":"86","author":"RS Chamberlain","year":"1999","unstructured":"Chamberlain RS, Blumgart LH. Carcinoid tumors of the extrahepatic bile duct. A rare cause of malignant biliary obstruction. Cancer. 1999;86(10):1959\u201365.","journal-title":"Cancer"},{"issue":"2","key":"1302_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jamcollsurg.2007.02.076","volume":"205","author":"CR Ferrone","year":"2007","unstructured":"Ferrone CR, Tang LH, D\u2019Angelica M, DeMatteo RP, Blumgart LH, Klimstra DS, et al. Extrahepatic bile duct carcinoid tumors: malignant biliary obstruction with a good prognosis. J Am Coll Surg. 2007;205(2):357\u201361. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2007.02.076.","journal-title":"J Am Coll Surg"},{"issue":"5","key":"1302_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/jclinpath-2012-201273","volume":"66","author":"K Harada","year":"2013","unstructured":"Harada K, Sato Y, Ikeda H, Hsu M, Igarashi S, Nakanuma Y. Notch1-Hes1 signalling axis in the tumourigenesis of biliary neuroendocrine tumours. J Clin Pathol. 2013;66(5):386\u201391. https:\/\/doi.org\/10.1136\/jclinpath-2012-201273.","journal-title":"J Clin Pathol"},{"key":"1302_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7931975","volume":"2017","author":"ME Ibrahim","year":"2017","unstructured":"Ibrahim ME, Abadeer K, Zhai QJ, Nassar A. Primary hepatic neuroendocrine tumor with unusual thyroid follicular-like morphologic characteristics. Case Rep Pathol. 2017;2017: 7931975. https:\/\/doi.org\/10.1155\/2017\/7931975.","journal-title":"Case Rep Pathol"},{"issue":"1","key":"1302_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00268-004-7443-z","volume":"29","author":"IM Modlin","year":"2005","unstructured":"Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005;29(1):92\u2013101. https:\/\/doi.org\/10.1007\/s00268-004-7443-z.","journal-title":"World J Surg"},{"issue":"2","key":"1302_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153\u201371. https:\/\/doi.org\/10.1159\/000443171.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1302_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","journal-title":"Endocr Pathol"},{"issue":"9","key":"1302_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/pas.0000000000000662","volume":"40","author":"LH Tang","year":"2016","unstructured":"Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192\u2013202. https:\/\/doi.org\/10.1097\/pas.0000000000000662.","journal-title":"Am J Surg Pathol"},{"key":"1302_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.humpath.2019.12.002","volume":"96","author":"AM Bellizzi","year":"2020","unstructured":"Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol. 2020;96:8\u201333. https:\/\/doi.org\/10.1016\/j.humpath.2019.12.002.","journal-title":"Hum Pathol"},{"issue":"3","key":"1302_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000472254","volume":"105","author":"K Oberg","year":"2017","unstructured":"Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201\u201311. https:\/\/doi.org\/10.1159\/000472254.","journal-title":"Neuroendocrinology"},{"issue":"8","key":"1302_CR15","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1210\/jcem.82.8.4145","volume":"82","author":"FR Nobels","year":"1997","unstructured":"Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82(8):2622\u20138. https:\/\/doi.org\/10.1210\/jcem.82.8.4145.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1302_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1365-2265.2004.02030.x","volume":"60","author":"D Nehar","year":"2004","unstructured":"Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004;60(5):644\u201352. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02030.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1302_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.cgh.2008.02.052","volume":"6","author":"R Arnold","year":"2008","unstructured":"Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, et al. Plasma chromogranin a as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008;6(7):820\u20137. https:\/\/doi.org\/10.1016\/j.cgh.2008.02.052.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1302_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1097\/mpa.0000000000001184","volume":"47","author":"RE Rossi","year":"2018","unstructured":"Rossi RE, Ciafardini C, Sciola V, Conte D, Massironi S. Chromogranin A in the follow-up of gastroenteropancreatic neuroendocrine neoplasms: is it really game over? A systematic review and meta-analysis. Pancreas. 2018;47(10):1249\u201355. https:\/\/doi.org\/10.1097\/mpa.0000000000001184.","journal-title":"Pancreas"},{"key":"1302_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081113","author":"A Sansone","year":"2019","unstructured":"Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, et al. Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11081113.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1302_CR20","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/erc-17-0269","volume":"25","author":"V Marotta","year":"2018","unstructured":"Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2018;25(1):R11\u201329. https:\/\/doi.org\/10.1530\/erc-17-0269.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1302_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.bpg.2012.12.006","volume":"26","author":"G Kanakis","year":"2012","unstructured":"Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26(6):791\u2013802. https:\/\/doi.org\/10.1016\/j.bpg.2012.12.006.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"1302_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1530\/erc-15-0092","volume":"22","author":"M Kidd","year":"2015","unstructured":"Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561\u201375. https:\/\/doi.org\/10.1530\/erc-15-0092.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1302_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2018.05.002","volume":"47","author":"IM Modlin","year":"2018","unstructured":"Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, et al. The NETest: the clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors. Endocrinol Metab Clin North Am. 2018;47(3):485\u2013504. https:\/\/doi.org\/10.1016\/j.ecl.2018.05.002.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"1302_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00259-015-3250-z","volume":"43","author":"L Bodei","year":"2016","unstructured":"Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43(5):839\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3250-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1302_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.annonc.2021.08.1746","volume":"32","author":"IM Modlin","year":"2021","unstructured":"Modlin IM, Kidd M, Falconi M, Filosso PL, Frilling A, Malczewska A, et al. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Ann Oncol. 2021;32(11):1425\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1746.","journal-title":"Ann Oncol"},{"issue":"10","key":"1302_CR26","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","volume":"69","author":"J Davar","year":"2017","unstructured":"Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69(10):1288\u2013304. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.030.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1302_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.mric.2018.03.010","volume":"26","author":"GC Lo","year":"2018","unstructured":"Lo GC, Kambadakone A. MR imaging of pancreatic neuroendocrine tumors. Magn Reson Imaging Clin N Am. 2018;26(3):391\u2013403. https:\/\/doi.org\/10.1016\/j.mric.2018.03.010.","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"3","key":"1302_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212\u201344. https:\/\/doi.org\/10.1159\/000471879.","journal-title":"Neuroendocrinology"},{"issue":"5","key":"1302_CR29","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"9","key":"1302_CR30","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.7150\/thno.98053","volume":"14","author":"A Akhavanallaf","year":"2024","unstructured":"Akhavanallaf A, Joshi S, Mohan A, Worden FP, Krauss JC, Zaidi H, et al. Enhancing precision: a predictive model for (177)Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative (68)Ga-DOTATATE PET and clinicopathological biomarkers. Theranostics. 2024;14(9):3708\u201318. https:\/\/doi.org\/10.7150\/thno.98053.","journal-title":"Theranostics"},{"issue":"1","key":"1302_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jgh.13585","volume":"32","author":"I Sano","year":"2017","unstructured":"Sano I, Kuwatani M, Sugiura R, Kato S, Kawakubo K, Ueno T, et al. Hepatobiliary and pancreatic: a rare case of a well-differentiated neuroendocrine tumor in the bile duct with spontaneous regression diagnosed by EUS-FNA. J Gastroenterol Hepatol. 2017;32(1):11\u201311. https:\/\/doi.org\/10.1111\/jgh.13585.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1302_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/dc.24334","volume":"48","author":"M Ishida","year":"2020","unstructured":"Ishida M, Okano K, Sandoh K, Ito H, Ikeura T, Mitsuyama T, et al. Neuroendocrine carcinoma diagnosis from bile duct cytological specimens: a retrospective single-center study. Diagn Cytopathol. 2020;48(2):154\u20138. https:\/\/doi.org\/10.1002\/dc.24334.","journal-title":"Diagn Cytopathol"},{"issue":"24","key":"1302_CR33","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.3748\/wjg.v24.i24.2640","volume":"24","author":"XF Meng","year":"2018","unstructured":"Meng XF, Pan YW, Wang ZB, Duan WD. Primary hepatic neuroendocrine tumor case with a preoperative course of 26 years: a case report and literature review. World J Gastroenterol. 2018;24(24):2640\u20136. https:\/\/doi.org\/10.3748\/wjg.v24.i24.2640.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1302_CR34","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1245\/aso.2003.04.533","volume":"10","author":"CD Knox","year":"2003","unstructured":"Knox CD, Anderson CD, Lamps LW, Adkins RB, Pinson CW. Long-term survival after resection for primary hepatic carcinoid tumor. Ann Surg Oncol. 2003;10(10):1171\u20135. https:\/\/doi.org\/10.1245\/aso.2003.04.533.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1302_CR35","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.dld.2011.07.010","volume":"43","author":"J Kim","year":"2011","unstructured":"Kim J, Lee WJ, Lee SH, Lee KB, Ryu JK, Kim YT, et al. Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours. Dig Liver Dis. 2011;43(12):965\u201370. https:\/\/doi.org\/10.1016\/j.dld.2011.07.010.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"1302_CR36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.anndiagpath.2009.08.002","volume":"13","author":"J Albores-Saavedra","year":"2009","unstructured":"Albores-Saavedra J, Batich K, Hossain S, Henson DE, Schwartz AM. Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the surveillance, epidemiology, and end results program. Ann Diagn Pathol. 2009;13(6):378\u201383. https:\/\/doi.org\/10.1016\/j.anndiagpath.2009.08.002.","journal-title":"Ann Diagn Pathol"},{"key":"1302_CR37","doi-asserted-by":"publisher","unstructured":"Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. Diagnosis and Treatment Guidelines for Neuroendocrine Tumors of the Chinese Anti-Cancer Association (2025 Edition). China Oncology. 2025;35(01):85\u2013142.https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2025.01.010","DOI":"10.19401\/j.cnki.1007-3639.2025.01.010"},{"issue":"6","key":"1302_CR38","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdh216","volume":"15","author":"K Oberg","year":"2004","unstructured":"Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdh216.","journal-title":"Ann Oncol"},{"issue":"2","key":"1302_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"67","key":"1302_CR40","first-page":"33","volume":"53","author":"M Abdel Wahab","year":"2006","unstructured":"Abdel Wahab M, Fathy O, Elghwalby N, Sultan A, Mostafa M, El-Baz M, et al. Primary hepatic carcinoid tumor: one Egyptian center experience. Hepatogastroenterology. 2006;53(67):33\u20138.","journal-title":"Hepatogastroenterology"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01302-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:03:19Z","timestamp":1757448199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01302-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01302-z","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"12 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Jilin University. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Informed written consent was obtained from the patient for publication of this report and any accompanying images. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}